MAP2K1 and Miyoshi myopathy: We then asked whether co‐treatment of MM cells with low doses (IC10) of the PIs and MEK 1/2 (CI‐1040) or JNK 1/2/3 (JNK‐IN‐8) inhibitors exert synergistic effects.